Disease · MONDO_0001409

esophagitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. esophagitis. Diseases, record MONDO_0001409. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001409

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: esophagitis; Open Targets
Open Targets ID: MONDO_0001409; Open Targets
Other names: Inflammation of the esophagus, Inflammation of the oesophagus, Oesophagitis, esophagitis (disease), esophagus inflammation, inflammation of esophagus, inflammation of oesophagus, oesophagus inflammation; Open Targets
Disease Ontology: DOID:11963; Disease Ontology
MeSH: D004941; MeSH
NCI Thesaurus: C9224; NCI Thesaurus
Highest stage of its drugs: Approval, for 9 of its 33 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs33

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMEPRAZOLE	CHEMBL1503	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets
DEXLANSOPRAZOLE	CHEMBL1201863	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
PANTOPRAZOLE SODIUM	CHEMBL3989559	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
ESOMEPRAZOLE MAGNESIUM	CHEMBL5314366	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
FAMOTIDINE	CHEMBL902	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
DUPILUMAB	CHEMBL2108675	Antibody	Approval	EMA Human Drugs	1	0	0	Drugs and targets
NIZATIDINE	CHEMBL3183075	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
SODIUM BICARBONATE	CHEMBL1353	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ESOMEPRAZOLE	CHEMBL1201320	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 33

See all 33 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	9	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	9	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/1268	Drugs and targets
HRH2	Histamine H2 receptor	2	Histamine H2 receptor antagonist	Approval	https://conductscience.org/library/genes/3274	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1441	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1956	Drugs and targets
HRH1	Histamine H1 receptor	1	Histamine H1 receptor agonist	Unknown	https://conductscience.org/library/genes/3269	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Approval	https://conductscience.org/library/genes/3566	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TOP1	DNA topoisomerase 1	1	DNA topoisomerase I inhibitor	Phase 1/2	https://conductscience.org/library/genes/7150	Drugs and targets

1 to 10 of 28

See all 28 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01952847	Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis	Phase 3	77	2022-06-15	Advanced Cancers	GLUTAMINE	Its record names the disease	ClinicalTrials.gov
NCT00280150	Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer	Phase 1/2	46	2017-06-19	Lung Cancer	BEVACIZUMAB, CARBOPLATIN, ERLOTINIB HYDROCHLORIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04225026	Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer	Phase 2	39	2023-03-23	Esophagitis	AVASOPASEM MANGANESE	Its record names the disease	ClinicalTrials.gov
NCT01132638	Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease	Phase 3	713		GERD	ESOMEPRAZOLE, PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02860624	Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients	Phase 3	550		Gastroesophageal Reflux Disease	ESOMEPRAZOLE, ILAPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06953986	A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks	Not applicable	414		GERD	ESOMEPRAZOLE, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT01400945	Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease	Phase 3	154		Gastroesophageal Reflux Disease	PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02577393	Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy	Phase 2	83		Lung Neoplasms, Esophagitis, Prevention & Control, Epigallocatechin Gallate	EPIGALOCATECHIN GALLATE	Its record names the disease	ClinicalTrials.gov
NCT00006012	Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer	Phase 1/2	73		Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity	AMIFOSTINE, CISPLATIN, ETOPOSIDE, FILGRASTIM, PACLITAXEL, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01657578	Optimal Dosing of Omeprazole in Neonates	Phase 2	55		Gastroesophageal Reflux Disease (GERD)	OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Radiation Therapy to Esophagus Patient Group - Glutamine vs Radiation Therapy to Esophagus Patient Group - Placebo: Number of Participants With Cancer Treatment Interruptions Due to Esophagitis	0 of 19	0 of 19	38	NCT01952847	Trial comparisons
mTOR Inhibitor Patient Group - Glutamine vs mTOR Inhibitor Patient Group - Placebo: Number of Participants With Cancer Treatment Interruptions Due to Mucositis	0 of 7	0 of 6	13	NCT01952847	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23045594	RESULT	1	PubMed
17336213	RESULT	1	PubMed
33580845	DERIVED	1	PubMed
29540336	DERIVED	1	PubMed
24299323	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001409

GET https://conductscience.org/api/diseases/v1/MONDO_0001409/drugs?page=2

API reference For AI assistants